ZYME earnings analysis
What we found in ZYME's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Zymeworks reported a significant decline in revenue for Q1 2026, totaling $2.4 million, down 91% from $27.1 million in Q1 2025. The net loss for the quarter was $44.2 million, reflecting continued financial strain and indicating a need for funding despite maintaining cash reserves of $403.8 million. Management outlined a disciplined approach to expenses and a commitment to advancing the drug pipeline but acknowledged substantial operating losses ahead.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Declines Sharply
- Total revenue for Q1 2026 was $2.4 million, a 91% decline from $27.1 million in Q1 2025.
- Large Net Loss Reported
- Zymeworks posted a net loss of $44.2 million for Q1 2026, continuing the trend of significant losses.
- Cash Reserves Remain Strong
- As of March 31, 2026, cash, cash equivalents, and marketable securities stood at $403.8 million.
- R&D Spend Reduced
- Research and development expenses decreased by $1.2 million, reflecting a shift in program mix.
- Milestone Progress with Jazz
- Zymeworks anticipates future royalty revenues from Jazz as zanidatamab commercial sales increase.
- Discipline in Capital Allocation
- Management reiterated a commitment to disciplined capital allocation to support strategic objectives.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Dramatic Revenue Drop
- Total revenue declined by $24.7 million compared to Q1 2025, impacting financial viability.
- Increased Operating Losses
- Q1 2026 net loss of $44.2 million demonstrates ongoing financial challenges.
- Regulatory and Approval Risks
- If partnered product candidates do not meet regulatory approvals, revenues will be adversely affected.
What they said about what is next.
The company reiterated a disciplined operating expense target of approximately $300 million through 2028.
The filing reads worse than the one before it.
What came before.
- 10-K · March 2, 2026
- Zymeworks positions itself as a royalty- and asset-aggregation biotech combining partnered royalties/milestones with selective internal R&D. The company secured a $250.0 million royalty-backed note financing against 30%…
- 10-Q · August 7, 2025
- Zymeworks reported Q2 revenue of $48,726 (amounts in filing are in thousands), up from $19,243 in Q2 2024, and delivered net income of $2,317 producing EPS of $0.03. Operating loss narrowed sharply to $(674) for the…
- 10-Q · May 8, 2025
- Zymeworks reported Q1 2025 revenue of $27,110 (amounts in the filing are expressed in thousands) versus $10,030 in Q1 2024, driving a meaningful beat to consensus and a large YoY increase. Loss from operations narrowed…
- 10-K · March 6, 2024
- Zymeworks' 2023 10-K emphasizes a partnership-led commercialization strategy for lead candidate zanidatamab, with $375.0 million received from Jazz and $53.0 million received from BeiGene through December 31, 2023. The…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ZYME makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever